Arkolith/Insider Trading/TALS/Form 4

Fenton Mary Kay

Chief Financial OfficerTalaris Therapeutics, Inc. (TALS) · full profile →Form 4 · filed Jul 6, 2023
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
1
1 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jul 3, 2023Tax withholding(F)13K$3.08$40K68K

Transaction Codes

F
Shares withheld for taxes

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001209191-23-041617) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML